Showing 4 results for Therapy
Many businesses and academic researchers wishing to pursue cutting-edge research ideas with government support lack the resources to navigate the burdensome paperwork requirements required to win federal grants or contracts. DARPA’s Biological Technologies Office (BTO) has created a simplified proposal process to attract and fund new ideas from just those types of innovators—those operating at the intersection of biology and technology who may never have worked with the Defense Department and may otherwise have remained too daunted to try.
May 17, 2019,
Executive Conference Center
The Biological Technologies Office is holding a Proposers Day meeting to provide information to potential proposers on the objectives of the new ReVector program and to facilitate teaming. The goal of ReVector is to develop an easily delivered treatment — for example, a topical solution — that safely and temporarily modifies the human skin microbiome to alter scents and thereby reduce attraction of disease-spreading mosquitoes.
Military service members and veterans face serious occupational trauma; one
element in particular relates to the significantly increased risk of acute
and chronic neuropsychiatric conditions. Neuropsychiatric conditions in the
military are particularly impactful because options for treating them are
limited. No therapy currently exists that can deliver rapid relief of
neuropsychiatric symptoms and is reasonable for use in a broad spectrum of
conditions. Neuropsychiatric conditions are complex, and presentation is
highly subject to significant inter-individual variability. Focused Pharma
aims to develop new drugs that target specific neurotransmitter receptor
signaling modes to deliver near immediate relief that is generalizable
across indications and individuals.
The Defense Advanced Research Projects Agency (DARPA) Small Business Programs Office (SBPO) is issuing an SBIR/STTR Opportunity (SBO) inviting submissions of innovative research concepts in the technical domain of Biomedical Technology. In particular, DARPA is interested in understanding the feasibility of Patterned, Responsive Cellular Therapies Using Novel Mammalian Cellular Regulator Systems.